Tirzepatide emerges a groundbreaking therapeutic agent for individuals facing type 2 diabetes. As a dual stimulator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://abelebtg095114.activosblog.com/39188752/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist